Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Non Operating Income (2018 - 2026)

Corcept Therapeutics (CORT) has disclosed Non Operating Income for 9 consecutive years, with $4.9 million as the latest value for Q1 2026.

  • For Q1 2026, Non Operating Income fell 21.22% year-over-year to $4.9 million; the TTM value through Mar 2026 reached $20.3 million, down 19.4%, while the annual FY2025 figure was $21.7 million, 11.72% down from the prior year.
  • Non Operating Income hit $4.9 million in Q1 2026 for Corcept Therapeutics, down from $5.4 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $6.7 million in Q4 2024 and bottomed at $80000.0 in Q1 2022.
  • Average Non Operating Income over 5 years is $4.2 million, with a median of $5.0 million recorded in 2025.
  • Year-over-year, Non Operating Income plummeted 70.91% in 2022 and then soared 4376.25% in 2023.
  • Corcept Therapeutics' Non Operating Income stood at $1.8 million in 2022, then skyrocketed by 189.25% to $5.1 million in 2023, then surged by 30.31% to $6.7 million in 2024, then dropped by 19.04% to $5.4 million in 2025, then fell by 9.9% to $4.9 million in 2026.
  • According to Business Quant data, Non Operating Income over the past three periods came in at $4.9 million, $5.4 million, and $5.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.